机构

• 上海药物研究所 [11]
• 武汉病毒研究所 [1]
• 昆明植物研究所 [1]

采集方式

• OAI收割 [12]
• iSwitch采集 [1]

内容类型

• 期刊论文 [13]

发表日期

• 2023 [4]
• 2022 [1]
• 2021 [2]
• 2018 [3]
• 2017 [1]
• 2012 [1]
• 更多

学科主题

• Pharmacolo... [1]
• Toxicology [1]

筛选

浏览/检索结果: 共13条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序发表日期升序发表日期降序题名升序题名降序作者升序作者降序 Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities 期刊论文  OAI收割 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 卷号: 259, 页码: 19 作者:  Wang, Pingyuan;  Zhu, Wen-Ting;  Wang, Yajing;  Song, Shan-Shan;  Xi, Yong   |  收藏  |  浏览/下载：58/0  |  提交时间：2023/10/17 PARP1 inhibitor  Synthetic lethality  Drug resistance  Anticancer  Structure -activity relationship   Advancements and Obstacles of PARP Inhibitors in Gastric Cancer 期刊论文  OAI收割 CANCERS, 2023, 卷号: 15, 期号: 21, 页码: 19 作者:  Chen, Hongjie;  Hu, Yangchan;  Zhuang, Zirui;  Wang, Dingyi;  Ye, Zu   |  收藏  |  浏览/下载：3/0  |  提交时间：2023/12/19 gastric cancer  DNA damage repair  PARP inhibitor  cancer therapy   Heparin mimetics as potential intervention for COVID-19 and their bio-manufacturing 期刊论文  OAI收割 SYNTHETIC AND SYSTEMS BIOTECHNOLOGY, 2023, 卷号: 8, 期号: 1, 页码: 11-19 作者:  Jiang, Lan;  Zhang, Tianji;  Lu, Hongzhong;  Li, Saijuan;  Lv, Kangjie   |  收藏  |  浏览/下载：14/0  |  提交时间：2023/04/10 Heparin  Biosynthesis  Biological activities  Bio-production   Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance 期刊论文  OAI收割 EMBO MOLECULAR MEDICINE, 2023, 页码: 24 作者:  Wang, Li-Min;  Wang, Pingyuan;  Chen, Xiao-Min;  Yang, Hui;  Song, Shan-Shan   |  收藏  |  浏览/下载：21/0  |  提交时间：2023/04/10 homologous recombination repair  olaparib-resistant  PARP inhibitor  PARP7  type I interferons   Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone 期刊论文  OAI收割 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 卷号: 240, 页码: 114574 作者:  Kayumov, Muzaffar;  Jia, Li;  Pardaev, Azizbek;  Song, Shan-Shan;  Mirzaakhmedov, Sharafitdin   |  收藏  |  浏览/下载：12/0  |  提交时间：2024/03/21 PARP1  Olaparib  Alantolactone  Syntheticlethality  BRCA1/2mutant   Nosiheptide analogues as potential antibacterial agents via dehydroalanine region modifications: Semi-synthesis, antimicrobial activity and molecular docking study 期刊论文  OAI收割 BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 卷号: 31, 页码: 10 作者:  Fan, Yafei;  Chen, Hangfei;  Mu, Ning;  Wang, Wengui;  Zhu, Kongkai   |  收藏  |  浏览/下载：23/0  |  提交时间：2021/05/24 Nosiheptide analogues  Semi-synthesis  Antimicrobial activity  Molecular docking   TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models 期刊论文  OAI收割 AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 卷号: 11, 期号: 4, 页码: 1632-1645 作者:  Wang, Lei;  Zhu, Xi;  Li, Lili;  Li, Lin;  Fu, Li   |  收藏  |  浏览/下载：20/0  |  提交时间：2021/06/11 PARP  DNA damage  hematologic toxicity  beta-glucuronidase  tumor selectivity   Lipid-Based Liquid Crystalline Nanoparticles Facilitate Cytosolic Delivery of siRNA via Structural Transformation 期刊论文  OAI收割 NANO LETTERS, 2018, 卷号: 18, 期号: 4, 页码: 2411-2419 作者:  He, Shufang;  Fan, Weiwei;  Wu, Na;  Zhu, Jingjing;  Miao, Yunqiu   |  收藏  |  浏览/下载：28/0  |  提交时间：2019/01/08 Lipids  liquid crystalline nanoparticles  siRNA delivery  endosomal escape  synthetic lethality   Facilitating Anti-Cancer Combinatorial Drug Discovery by Targeting Epistatic Disease Genes 期刊论文  OAI收割 Molecules (Basel, Switzerland), 2018, 卷号: 23, 期号: 4 作者:  Quan, Yuan;  Liu, Meng-Yuan;  Liu, Ye-Mao;  Zhu, Li-Da;  Wu, Yu-Shan   |  收藏  |  浏览/下载：22/0  |  提交时间：2019/01/08 Targeting death receptors for drug-resistant cancer therapy: Codelivery of pTRAIL and monensin using dual-targeting and stimuli-responsive self-assembling nanocomposites 期刊论文  OAI收割 BIOMATERIALS, 2018, 卷号: 158, 页码: 56-73 作者:  Xu, Fan;  Zhong, Huihai;  Chang, Ya;  Li, Dongdong;  Jin, Hongyue   |  收藏  |  浏览/下载：49/0  |  提交时间：2019/01/08 TRAIL  Gene delivery  Monensin  Poly-gamma-glutamic acid  Death receptor  Drug resistance